Marriage Counselors in Cleveland Heights, OH Accepting Medicare

4 Marriage Counselors found. Showing 1 - 4

Mrs. Zoey Greer Holguin, LMFT, IMFT-S Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 2460 Fairmount Blvd Ste 326, Cleveland Heights, OH 44106 Phone: 440-836-3186    Fax: 440-815-2423

Randie Shane, IMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 2460 Fairmount Blvd, #326, Cleveland Heights, OH 44106 Phone: 917-478-1254

Molly Simkins Sluk, MA Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 12429 Cedar Rd Ste 7, Cleveland Heights, OH 44106 Phone: 206-790-2364    Fax: 888-972-7936

Peter Damian Simkins Sluk, MA, IMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 3256 Ormond Rd, Cleveland Heights, OH 44118 Phone: 216-577-3333

News Archive

Moderate alcohol consumption and diabetes – benefits are found in new study

There have been several studies that have connected excessive drinking to type 2 diabetes. However, there are no studies that have actually looked at the drinking patterns and frequency and diabetes. Danish researchers have thus tried to understand the connection and explore if moderate alcohol consumption has a beneficial effect on diabetes. This new study was published this week in the journal Diabetologia.

Good cholesterol helps SARS-CoV-2 enter cells

The researchers explained that the SARS-CoV-2 can infect human host cells after its viral spike protein (SARS-2-S) binds to a cellular surface receptor called the angiotensin-converting enzyme 2 (ACE2).

Optical and PET/CT activity-based probes could help in non-invasive imaging of atherosclerotic plaques

Researchers at Stanford University have demonstrated for the first time the use of a dual optical and PET/CT activity-based probe to detect atherosclerotic plaques. The study is published in the October issue of the Journal of Nuclear Medicine.

Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial

Genzyme Corporation today reported five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial. This sub-group analysis found that nearly 90 percent of alemtuzumab-treated patients were free of sustained accumulation of disability, and that patients receiving alemtuzumab also maintained improved mean disability scores and a low risk of relapse over the 60-month follow-up period.

Read more Medical News

› Verified 2 days ago